DBSolveOptimum 2020 provides extended opportunities for QSP modeling
[Moscow, Russia – 06.10.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases the new version of mathematical simulation workbench DBSolveOptimum 2020. It represents a significantly advanced and extended successor of the well-known simulation software DBSolveOptimum described in the paper [PMID 20698988] published in 2010. DBSolve is a user friendly simulation software package that enables to simplify the development, calibration and analysis of QSP models.
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
IRT 3.2.0 acquires new models and extended annotations
(Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.
First
Prev